292 related articles for article (PubMed ID: 21423660)
21. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
23. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
24. Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice.
Yoon N; Park MS; Peltier GC; Lee RH
Cytotherapy; 2015 Oct; 17(10):1332-41. PubMed ID: 26227206
[TBL] [Abstract][Full Text] [Related]
25. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
27. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
28. Noscapine inhibits human hepatocellular carcinoma growth through inducing apoptosis in vitro and in vivo.
Xu G; Niu Z; Dong J; Zhao Y; Zhang Y; Li X
Neoplasma; 2016; 63(5):726-33. PubMed ID: 27468876
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis.
Yang C; Ran Q; Zhou Y; Liu S; Zhao C; Yu X; Zhu F; Ji Y; Du Q; Yang T; Zhang W; He S
Apoptosis; 2020 Jun; 25(5-6):441-455. PubMed ID: 32418059
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
[TBL] [Abstract][Full Text] [Related]
31. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines.
Kocak C; Kocak FE; Ozturk B; Tekin G; Vatansev H
Bratisl Lek Listy; 2020; 121(1):43-50. PubMed ID: 31950839
[TBL] [Abstract][Full Text] [Related]
33. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
[TBL] [Abstract][Full Text] [Related]
34. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
35. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
Pateliya B; Burade V; Goswami S
Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
[TBL] [Abstract][Full Text] [Related]
36. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
38. Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway.
Hajra S; Patra AR; Basu A; Saha P; Bhattacharya S
Chem Biol Interact; 2018 Jun; 290():19-36. PubMed ID: 29775573
[TBL] [Abstract][Full Text] [Related]
39. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.
Wang S; Liu Q; Zhang Y; Liu K; Yu P; Liu K; Luan J; Duan H; Lu Z; Wang F; Wu E; Yagasaki K; Zhang G
Mol Cancer; 2009 Oct; 8():81. PubMed ID: 19796390
[TBL] [Abstract][Full Text] [Related]
40. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]